The Prognostic Value of Peripheral CD4+CD25+ T Lymphocytes Among Early Stage and Triple Negative Breast Cancer Patients Receiving Dendritic Cells-cytokine Induced Killer Cells Infusion

Overview

Journal Oncotarget

Specialty Oncology

Date 2015 Oct 14

PMID 26462021

Citations 8

Authors

Qing-Kun Song

Jun Ren

Xin-Na Zhou

Xiao-Li Wang

Guo-Hong Song

Li-Jun Di

Jing Yu

Amy Hobeika

Michael A Morse

Yan-Hua Yuan

Hua-Bing Yang

Herbert Kim Lyerly

Affiliations

Soon will be listed here.

Abstract

Objective: This study aimed to assess the prognostic value of CD4+CD25+ T lymphocyte in peripheral blood among breast cancer patients treated with adoptive T lymphocytes immunotherapy.

Methods: 217 patients participated in the follow-up study. CD4+CD25+ proportion was measured by flow cytometry in peripheral T cells. The median survival was estimated by Kaplan-Meier curve, Log-rank test and Cox hazard proportion regression model, between groups of CD4+CD25+ proportion more than 5% and less than or equal to 5% in peripheral T cells.

Results: Peripheral CD4+CD25+ T lymphocytes had not a relationship with progression-free survival. It was featured that above 5% peripheral CD4+CD25+ proportion of T cells was related with the median overall survival by a shorten of 51 months (p < 0.05) with the HR 1.65 (95%CI 1.04, 2.62). Above 5% CD4+CD25+proportion of T cells produced the HR to be 1.76 (95%CI 1.07, 2.87) In stage 0-II patients, and 3.59 (95%CI 1.05, 12.29) in triple negative breast cancer patients.

Conclusions: Cellular immunity restoration recovered by adoptive T cell infusions which resulted in less proportion of peripheral CD4+CD25+T lymphocytes could be a potential prognostic indicator among early stage and triple negative patients.

Citing Articles

Combined oral low-dose cyclophosphamide endocrine therapy may improve clinical response among patients with metastatic breast cancer via Tregs in TLSs.

Zhao Y, Wang S, Lv S, Liu X, Li W, Song Y Sci Rep. 2024; 14(1):13432.

PMID: 38862586 PMC: 11166640. DOI: 10.1038/s41598-024-64042-3.

LAP+CD4+T cells regulate the anti-tumor role of CIK cells in colorectal cancer through IL-10 and TGF-β.

Zhong W, Fang C, Liu H, Zhang L, Zhang X, Zhong J Am J Transl Res. 2022; 14(6):3716-3728.

PMID: 35836905 PMC: 9274552.

A Neutrophil Extracellular Traps Signature Predicts the Clinical Outcomes and Immunotherapy Response in Head and Neck Squamous Cell Carcinoma.

Chen N, He D, Cui J Front Mol Biosci. 2022; 9:833771.

PMID: 35252353 PMC: 8894649. DOI: 10.3389/fmolb.2022.833771.

Clinical efficacy of intra-cavitary infusions of autologous dendritic cell/cytokine-induced killer cell products for the treatment of refractory malignant pleural effusions and ascites.

He Z, Wang S, Qiao G, Wang X, Zhou X, Zhu S Am J Transl Res. 2020; 12(7):3940-3952.

PMID: 32774747 PMC: 7407744.

Predictive significance of T cell subset changes during generation of adoptive cellular therapy products for the treatment of advanced non-small cell lung cancer.

Huang L, Qiao G, Morse M, Wang X, Zhou X, Wu J Oncol Lett. 2019; 18(6):5717-5724.

PMID: 31788044 PMC: 6865835. DOI: 10.3892/ol.2019.10964.

References

Song G, Wang X, Jia J, Yuan Y, Wan F, Zhou X . Elevated level of peripheral CD8(+)CD28(-) T lymphocytes are an independent predictor of progression-free survival in patients with metastatic breast cancer during the course of chemotherapy. Cancer Immunol Immunother. 2013; 62(6):1123-30. PMC: 11029068. DOI: 10.1007/s00262-013-1424-8. View

Keenan B, Saenger Y, Kafrouni M, Leubner A, Lauer P, Maitra A . A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice. Gastroenterology. 2014; 146(7):1784-94.e6. PMC: 4035450. DOI: 10.1053/j.gastro.2014.02.055. View

Xu L, Xu W, Jiang Z, Zhang F, Chu Y, Xiong S . Depletion of CD4(+)CD25(high) regulatory T cells from tumor infiltrating lymphocytes predominantly induces Th1 type immune response in vivo which inhibits tumor growth in adoptive immunotherapy. Cancer Biol Ther. 2008; 8(1):66-72. DOI: 10.4161/cbt.8.1.7131. View

Wang Z, Cao J, Wang M, Li D, Cui Y, Zhang X . Adoptive cellular immunotherapy for the treatment of patients with breast cancer: a meta-analysis. Cytotherapy. 2014; 16(7):934-45. DOI: 10.1016/j.jcyt.2014.02.011. View

Choudhury A, Palma M, Mellstedt H . The future of cancer vaccines for non-small-cell lung cancer: ongoing trials. Clin Lung Cancer. 2008; 9 Suppl 1:S37-44. DOI: 10.3816/clc.2008.s.006. View

Zhang Y, Yuan F, Jia G, Zhang J, Hu L, Huang L . CIK cells from patients with HCC possess strong cytotoxicity to multidrug-resistant cell line Bel-7402/R. World J Gastroenterol. 2005; 11(22):3339-45. PMC: 4315985. DOI: 10.3748/wjg.v11.i22.3339. View

Zhao Y, Jiang N, Song Q, Wu J, Song Y, Zhang H . Continuous DC-CIK infusions restore CD8+ cellular immunity, physical activity and improve clinical efficacy in advanced cancer patients unresponsive to conventional treatments. Asian Pac J Cancer Prev. 2015; 16(6):2419-23. DOI: 10.7314/apjcp.2015.16.6.2419. View

Hrubisko M, Sanislo L, Zuzulova M, Michalickova J, Zeleznikova T, Sedlak J . Immunity profile in breast cancer patients. Bratisl Lek Listy. 2010; 111(1):20-6. View

Schmidt J, Eisold S, Buchler M, Marten A . Dendritic cells reduce number and function of CD4+CD25+ cells in cytokine-induced killer cells derived from patients with pancreatic carcinoma. Cancer Immunol Immunother. 2004; 53(11):1018-26. PMC: 11032841. DOI: 10.1007/s00262-004-0554-4. View

10.

Jaberipour M, Habibagahi M, Hosseini A, Habibabad S, Talei A, Ghaderi A . Increased CTLA-4 and FOXP3 transcripts in peripheral blood mononuclear cells of patients with breast cancer. Pathol Oncol Res. 2010; 16(4):547-51. DOI: 10.1007/s12253-010-9256-8. View

11.

Demir L, Yigit S, Ellidokuz H, Erten C, Somali I, Kucukzeybek Y . Predictive and prognostic factors in locally advanced breast cancer: effect of intratumoral FOXP3+ Tregs. Clin Exp Metastasis. 2013; 30(8):1047-62. DOI: 10.1007/s10585-013-9602-9. View

12.

Song Q, Wang X, Zhou X, Yang H, Li Y, Wu J . Breast Cancer Challenges and Screening in China: Lessons From Current Registry Data and Population Screening Studies. Oncologist. 2015; 20(7):773-9. PMC: 4492227. DOI: 10.1634/theoncologist.2014-0351. View

13.

Lee S, Cho E, Park Y, Ahn J, Im Y . Prognostic impact of FOXP3 expression in triple-negative breast cancer. Acta Oncol. 2012; 52(1):73-81. DOI: 10.3109/0284186X.2012.731520. View

14.

Li H, Ren X, Zhang P, An X, Liu H, Hao X . [Dendritic cells reduce the number and function of CD4+CD25+ cells in cytokine-induced killer cells]. Zhonghua Yi Xue Za Zhi. 2006; 85(44):3134-8. View

15.

Abo-Elenein A, Elgohary S, Hashish A, El-Halaby E . Significance of immunoregulatory T cells in different stages of breast cancer patients. Egypt J Immunol. 2010; 15(2):145-52. View

16.

Wang Z, Yang B, Liu H, Hu Y, Yang J, Wu L . Regulatory T cells increase in breast cancer and in stage IV breast cancer. Cancer Immunol Immunother. 2011; 61(6):911-6. PMC: 11029076. DOI: 10.1007/s00262-011-1158-4. View

17.

Liu F, Lang R, Zhao J, Zhang X, Pringle G, Fan Y . CD8⁺ cytotoxic T cell and FOXP3⁺ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes. Breast Cancer Res Treat. 2011; 130(2):645-55. DOI: 10.1007/s10549-011-1647-3. View

18.

Hong C, Yao S, McCann S, Dolnick R, Wallace P, Gong Z . Pretreatment levels of circulating Th1 and Th2 cytokines, and their ratios, are associated with ER-negative and triple negative breast cancers. Breast Cancer Res Treat. 2013; 139(2):477-88. PMC: 3912696. DOI: 10.1007/s10549-013-2549-3. View

19.

Liu F, Li Y, Ren M, Zhang X, Guo X, Lang R . Peritumoral FOXP3⁺ regulatory T cell is sensitive to chemotherapy while intratumoral FOXP3⁺ regulatory T cell is prognostic predictor of breast cancer patients. Breast Cancer Res Treat. 2012; 135(2):459-67. DOI: 10.1007/s10549-012-2132-3. View

20.

Wang X, Ren J, Zhang J, Yan Y, Jiang N, Yu J . Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45). Clin Transl Oncol. 2015; 18(1):82-7. DOI: 10.1007/s12094-015-1339-2. View